Cell:内质网应激关键蛋白调节抗肿瘤免疫

2015-06-18 佚名 生物谷

近日,来自美国的研究人员在著名国际学术期刊Cell在线发表了一项最新研究进展,他们发现内质网应激应答因子XBP1能够通过调节脂质代谢影响DC细胞功能,抑制T细胞抗肿瘤免疫,促进肿瘤进展,为肿瘤免疫治疗的发展提供了一个重要线索。   本文亮点:   ●肿瘤微环境中的DC细胞存在ER应激和IRE1a/XBP1激活 ●DC细胞内的XBP1能够驱动原位和转移性卵巢癌进展

近日,来自美国的研究人员在著名国际学术期刊Cell在线发表了一项最新研究进展,他们发现内质网应激应答因子XBP1能够通过调节脂质代谢影响DC细胞功能,抑制T细胞抗肿瘤免疫,促进肿瘤进展,为肿瘤免疫治疗的发展提供了一个重要线索。
 
本文亮点:
 
●肿瘤微环境中的DC细胞存在ER应激和IRE1a/XBP1激活
●DC细胞内的XBP1能够驱动原位和转移性卵巢癌进展
●XBP1能够调节tDC细胞的脂质代谢和抗原递呈
●在tDC细胞中沉默XBP1能够增强T细胞抗肿瘤免疫延长宿主生存时间
 
树突状细胞(DC)在起始和维持T细胞依赖性抗肿瘤免疫中发挥着重要作用。但肿瘤常通过损伤正常DC细胞功能削弱免疫系统的控制。内质网应激应答因子XBP1能够直接促进肿瘤细胞生长,但XBP1是否具有调控宿主抗肿瘤免疫应答的作用仍不清楚。
 
在该项研究中,研究人员发现在肿瘤相关DC细胞中组成型激活的XBP1能够通过阻断抗肿瘤免疫驱动乳腺癌进展。XBP1的激活以脂质过氧化反应产生的副产物为动力,诱导tDC细胞中甘油三酯的合成模式发生改变,导致tDC细胞中脂质异常积累,抑制了tDC细胞对抗肿瘤T细胞功能发挥的促进作用。随后,研究人员在DC细胞中特异性删除XBP1或通过纳米颗粒介导的基因沉默方法在tDC细胞中特异性沉默XBP1表达,结果发现tDC细胞的免疫刺激活性得到恢复,同时也通过产生具有保护性的I型抗肿瘤免疫应答延长了宿主的生存时间。
 
总得来说,这项研究表明在DC细胞中靶向ER应激应答反应可以抑制肿瘤生长,增强抗肿瘤免疫,这一发现为肿瘤免疫治疗提供了一种重要的潜在方法,具有重要意义。
 


原始出处:

Cubillos-Ruiz JR1, Silberman PC2, Rutkowski MR3, Chopra S2, Perales-Puchalt A3, Song M2, Zhang S4, Bettigole SE5, Gupta D6, Holcomb K6, Ellenson LH7, Caputo T6, Lee AH7, Conejo-Garcia JR3, Glimcher LH8.ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.Cell. 2015 Jun 9. pii: S0092-8674(15)00575-9. doi: 10.1016/j.cell.2015.05.025. [Epub ahead of print]


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2017-01-17 wsasdeffgcf

    厉害了哦这个研究

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2016-04-23 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-09-20 zhouqu_8
  4. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 erhong

    有意思

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    有用

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    !!!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=170820, encodeId=babe1e0820a4, content=厉害了哦这个研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Jan 17 02:14:46 CST 2017, time=2017-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959397, encodeId=5fdd195939eba, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 23 18:27:00 CST 2016, time=2016-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869143, encodeId=dbe2186914328, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Sep 20 00:27:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027603, encodeId=9266202e603b8, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Oct 03 08:27:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29227, encodeId=ae3e2922e57, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:05:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28554, encodeId=abc12855434, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28500, encodeId=583928500e6, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28503, encodeId=365428503df, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:41:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28499, encodeId=cb2b28499db, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:40:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445102, encodeId=dd6e1445102fc, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:27:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]

相关资讯

默沙东、Plexxikon强势携手打造肿瘤免疫组合疗法

肿瘤是人类面临的最强大敌人之一。时至今日,尽管医学已经高度发达,科学家征服癌症依然是遥遥无期。不过,近几年兴起的肿瘤免疫疗法为人类最终战胜肿瘤病魔带来了一线曙光。最近,默沙东公司和Plexxikon公司宣布双方将联手进行肿瘤免疫组合疗法的研究,一旦成功,人类将在彻底征服肿瘤的道路上再前行一步。 众所周知,肿瘤难以根治的重要原因之一就是肿瘤细胞能够逃避人体免疫系统的监控。肿瘤免疫疗法的兴起相当

AACR 2015现场报道:热点——肿瘤免疫和免疫治疗

今天会议安排了4场以肿瘤免疫和免疫治疗为主题的专题交流,分别侧重于当今肿瘤免疫学研究的四个重点方向:肿瘤免疫逃逸、肿瘤免疫学研究进展的转化、免疫治疗中的生物标志物、以及检测点阻断治疗。在一些其它的专题交流会上,肿瘤免疫治疗也有散在报告,如肿瘤微环境专题交流。晚上,肿瘤免疫研究协作组和肿瘤微环境研究协作组联合举行了一场专题交流会,其中除了探讨肿瘤微环境对免疫功能的影响以外,也专门讨论了检测点阻断治疗

Bellicum建立肿瘤免疫疗法工厂

CAR-T疗法是目前的肿瘤疗法明星,其出色的疗效令许多产业人士和投资者所瞩目。随着数年的研究,这一疗法已经日趋成熟。许多进入这一领域的生物医药公司都开始考虑CAR-T疗法量产的问题。 最近,在肿瘤免疫疗法研究领域中颇为活跃的Bellicum Pharmaceuticals宣布公司已经决定自己建立一处专门用于生产细胞疗法相关产品的工厂。这处总面积达27000平方英尺的工厂位于Bellicum公司的

默克雪兰诺启动抗PD-L1免疫疗法II期临床研究

默克(Merck KGaA)旗下默克雪兰诺(EMD Serono)7月29日宣布,启动一项II期研究,评估抗PD-L1免疫疗法MSB0010718C治疗转移性Merkel细胞癌(mMCC)的疗效和安全性。该项研究是一项多中心、单组、开放标签研究,预计将在亚太、澳大利亚、欧洲和北美招募84例既往接受过一线化疗的mMCC患者,研究的主要终点是总缓解率。 PD-1/PD-L1作为免疫球蛋白超家族协

Immunity:补体是放疗诱导的特异性肿瘤免疫和临床反应的中央介质

免疫系统对肿瘤的杀伤作用是目前大家普遍接受的事实。比如,研究者们发现肿瘤组织内部效应T细胞的浸入与患者的存活期存在正向相关性;另外,在免疫系统受到抑制的患者体内更容易滋生肿瘤。然而,尽管肿瘤患者体内大多存在癌细胞特异性的免疫反应,临床上真正依靠免疫反应将肿瘤清除的病例却十分罕见。目前流行的肿瘤免疫疗法,比如"免疫检查点疗法"等强调了癌细胞特异性免疫反应的作用。 放射性疗法能够造成细胞DNA不